{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:02:21Z","timestamp":1791975741735,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-342-4531"],"award-info":[{"award-number":["IN-US-342-4531"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007250"],"award-info":[{"award-number":["T32DA007250"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA015815"],"award-info":[{"award-number":["UG1DA015815"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K24AA022523"],"award-info":[{"award-number":["K24AA022523"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Hepatitis C virus (HCV) is highly prevalent among homeless persons, yet barriers continue to impede HCV testing and treatment in this population. We studied the experiences of homeless individuals related to accessing HCV care to inform the design of a shelter-based HCV prevention and treatment program.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Homeless shelter clients (10 women and 10 men) of a large shelter in San Francisco participated in gender segregated focus groups. Focus groups followed a semi-structured interview format, which assessed individual, program\/system, and societal-level barriers and facilitators to universal HCV testing and linkage to HCV care. Focus group interviews were transcribed, coded, and analyzed using thematic analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We identified key barriers to HCV testing and treatment at the individual level (limited knowledge and misconceptions about HCV infection, mistrust of health care providers, co-morbid conditions of substance use, psychiatric and chronic medical conditions), system level (limited advocacy for HCV services by shelter staff), and social level (stigma of homelessness). Individual, system, and social facilitators to HCV care described by participants included internal motivation, financial incentives, prior experiences with rapid HCV testing, and availability of affordable direct acting antiviral (DAA) treatment, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Interrelated individual- and social-level factors were the predominant barriers affecting homeless persons\u2019 decisions to engage in HCV prevention and treatment. Integrated models of care for homeless persons at risk for or living with HCV address many of these factors, and should include interventions to improve patient knowledge of HCV and the availability of effective treatments.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05103-6","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T12:03:08Z","timestamp":1590753788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Clients\u2019 perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-7132","authenticated-orcid":false,"given":"Carmen L.","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Konadu","family":"Fokuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Zevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"issue":"3","key":"5103_CR1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","volume":"69","author":"MG Hofmeister","year":"2019","unstructured":"Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019;69(3):1020\u201331. https:\/\/doi.org\/10.1002\/hep.30297.","journal-title":"Hepatology."},{"issue":"1","key":"5103_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12889-017-4102-5","volume":"17","author":"K Page","year":"2017","unstructured":"Page K, Yu M, Cohen J, Evans J, Shumway M, Riley ED. HCV screening in a cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, California. BMC Public Health. 2017;17(1):171. https:\/\/doi.org\/10.1186\/s12889-017-4102-5.","journal-title":"BMC Public Health"},{"issue":"6","key":"5103_CR3","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s10900-019-00679-w","volume":"44","author":"Daniel Fuster","year":"2019","unstructured":"Fuster D, Gelberg L. Community screening, identification, and referral to primary care, for hepatitis C, B, and HIV among homeless persons in Los Angeles. J Community Health. May 2019. https:\/\/doi.org\/10.1007\/s10900-019-00679-w.","journal-title":"Journal of Community Health"},{"key":"5103_CR4","unstructured":"Centers for Disease Control and Prevention Viral Hepatitis Surveillance United States, 2016. Atlanta: US Department of health and human services, Centers for Disease Control and Prevention; 2018."},{"issue":"4","key":"5103_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/003335491212700409","volume":"127","author":"L Gelberg","year":"2012","unstructured":"Gelberg L, Robertson MJ, Arangua L, et al. Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Public Health Rep. 2012;127(4):407\u201321.","journal-title":"Public Health Rep"},{"issue":"3","key":"5103_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/JFN.0b013e31827a5908","volume":"9","author":"A Nyamathi","year":"2013","unstructured":"Nyamathi A, Salem BE, Marlow E, Zhang S, Yadav K. Understanding correlates of hepatitis C virus infection among homeless recently paroled men. J Forensic Nurs. 2013;9(3):161\u201370. https:\/\/doi.org\/10.1097\/JFN.0b013e31827a5908.","journal-title":"J Forensic Nurs"},{"issue":"1","key":"5103_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/apt.15291","volume":"50","author":"Jagpreet Chhatwal","year":"2019","unstructured":"Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther. May 2019. https:\/\/doi.org\/10.1111\/apt.15291.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"5103_CR8","first-page":"61","volume":"25","author":"H Bush","year":"2019","unstructured":"Bush H, Paik J, Golabi P, de Avila L, Escheik C, Younossi ZM. Impact of hepatitis C virus and insurance coverage on mortality. Am J Manag Care. 2019;25(2):61\u20137.","journal-title":"Am J Manag Care"},{"issue":"6","key":"5103_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2105\/AJPH.2017.303748","volume":"107","author":"JM Liao","year":"2017","unstructured":"Liao JM, Fischer MA. Restrictions of hepatitis C treatment for substance-using Medicaid patients: cost versus ethics. Am J Public Health. 2017;107(6):893\u20139. https:\/\/doi.org\/10.2105\/AJPH.2017.303748.","journal-title":"Am J Public Health"},{"issue":"9","key":"5103_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41395-018-0033-8","volume":"113","author":"RJ Wong","year":"2018","unstructured":"Wong RJ, Jain MK, Therapondos G, et al. Race\/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. Am J Gastroenterol. 2018;113(9):1329\u201338. https:\/\/doi.org\/10.1038\/s41395-018-0033-8.","journal-title":"Am J Gastroenterol"},{"key":"5103_CR11","doi-asserted-by":"publisher","unstructured":"Coyle C, Moorman AC, Bartholomew T, et al. The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA Hepatology March 2019. doi:https:\/\/doi.org\/10.1002\/hep.30501.","DOI":"10.1002\/hep.30501"},{"issue":"6","key":"5103_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/jvh.12512","volume":"23","author":"L Hawks","year":"2016","unstructured":"Hawks L, Norton BL, Cunningham CO, Fox AD. The hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. J Viral Hepat. 2016;23(6):473\u20138. https:\/\/doi.org\/10.1111\/jvh.12512.","journal-title":"J Viral Hepat"},{"issue":"4","key":"5103_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/0033354918772059","volume":"133","author":"JL Marcus","year":"2018","unstructured":"Marcus JL, Hurley LB, Chamberland S, et al. Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population. Public Health Rep. 2018;133(4):452\u201360. https:\/\/doi.org\/10.1177\/0033354918772059.","journal-title":"Public Health Rep"},{"issue":"1","key":"5103_CR14","doi-asserted-by":"publisher","first-page":"e000181","DOI":"10.1136\/bmjgast-2017-000181","volume":"4","author":"P Nguyen","year":"2017","unstructured":"Nguyen P, Vutien P, Hoang J, et al. Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-Centre experience. BMJ Open Gastroenterol. 2017;4(1):e000181. https:\/\/doi.org\/10.1136\/bmjgast-2017-000181.","journal-title":"BMJ Open Gastroenterol"},{"issue":"2","key":"5103_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.aohep.2018.06.001","volume":"18","author":"M Malespin","year":"2019","unstructured":"Malespin M, Harris C, Kanar O, et al. Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic. Ann Hepatol. 2019;18(2):304\u20139. https:\/\/doi.org\/10.1016\/j.aohep.2018.06.001.","journal-title":"Ann Hepatol"},{"key":"5103_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.drugpo.2019.03.017","volume":"72","author":"Marguerite E. Beiser","year":"2019","unstructured":"Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health Centre in Boston. Int J Drug Policy. April 2019. https:\/\/doi.org\/10.1016\/j.drugpo.2019.03.017.","journal-title":"International Journal of Drug Policy"},{"issue":"2","key":"5103_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/1468794112446106","volume":"13","author":"M O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly M, Parker N. \u2018Unsatisfactory saturation\u2019: a critical exploration of the notion of saturated sample sizes in qualitative research. Qual Res. 2013;13(2):190\u20137. https:\/\/doi.org\/10.1177\/1468794112446106.","journal-title":"Qual Res"},{"key":"5103_CR18","unstructured":"Krueger RA, Casey MA. Focus groups: a practical guide for applied research. 5th ed. Thousand Oaks, California: SAGE; 2015."},{"key":"5103_CR19","unstructured":"Lincoln YS, Guba EG. Naturalistic Inquiry. Nachdr. Newbury Park, Calif.: Sage; 20 (1985)."},{"issue":"2","key":"5103_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"1\u20132","key":"5103_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ypmed.2009.08.010","volume":"50","author":"R Bastani","year":"2010","unstructured":"Bastani R, Glenn BA, Taylor VM, et al. Integrating theory into community interventions to reduce liver cancer disparities: the health behavior framework. Prev Med. 2010;50(1\u20132):63\u20137. https:\/\/doi.org\/10.1016\/j.ypmed.2009.08.010.","journal-title":"Prev Med"},{"issue":"6","key":"5103_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.drugpo.2007.09.001","volume":"19","author":"J Neale","year":"2008","unstructured":"Neale J. Homelessness, drug use and hepatitis C: a complex problem explored within the context of social exclusion. Int J Drug Policy. 2008;19(6):429\u201335. https:\/\/doi.org\/10.1016\/j.drugpo.2007.09.001.","journal-title":"Int J Drug Policy."},{"issue":"2","key":"5103_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1525822X980100020301","volume":"10","author":"KM MacQueen","year":"1998","unstructured":"MacQueen KM, McLellan E, Kay K, Milstein B. Codebook development for team-based qualitative analysis. CAM Journal. 1998;10(2):31\u20136. https:\/\/doi.org\/10.1177\/1525822X980100020301.","journal-title":"CAM Journal"},{"issue":"2","key":"5103_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","volume":"156","author":"TF Baumert","year":"2019","unstructured":"Baumert TF, Berg T, Lim JK, Nelson DR. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology. 2019;156(2):431\u201345. https:\/\/doi.org\/10.1053\/j.gastro.2018.10.024.","journal-title":"Gastroenterology."},{"issue":"1","key":"5103_CR25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1353\/hpu.2017.0042","volume":"28","author":"M Beiser","year":"2017","unstructured":"Beiser M, Leon C, Gaeta JM. Needs assessment of HCV-infected individuals experiencing homelessness and implications. J Health Care Poor Underserved. 2017;28(1):596\u2013606. https:\/\/doi.org\/10.1353\/hpu.2017.0042.","journal-title":"J Health Care Poor Underserved"},{"key":"5103_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","volume":"100","author":"O Falade-Nwulia","year":"2019","unstructured":"Falade-Nwulia O, Irvin R, Merkow A, et al. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abus Treat. 2019;100:45\u201351. https:\/\/doi.org\/10.1016\/j.jsat.2019.01.021.","journal-title":"J Subst Abus Treat"},{"issue":"8","key":"5103_CR27","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/ajg.2015.31","volume":"110","author":"I Ditah","year":"2015","unstructured":"Ditah I, Al Bawardy B, Gonzalez HC, et al. Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and nutrition examination hepatitis C follow-up study. Am J Gastroenterol. 2015;110(8):1126\u201333. https:\/\/doi.org\/10.1038\/ajg.2015.31.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"5103_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7326\/M15-0406","volume":"163","author":"S Barua","year":"2015","unstructured":"Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of Sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215\u201323. https:\/\/doi.org\/10.7326\/M15-0406.","journal-title":"Ann Intern Med"},{"issue":"1","key":"5103_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11414-013-9333-3","volume":"41","author":"D Tyler","year":"2014","unstructured":"Tyler D, Nyamathi A, Stein JA, Koniak-Griffin D, Hodge F, Gelberg L. Increasing hepatitis C knowledge among homeless adults: results of a community-based, interdisciplinary intervention. J Behav Health Serv Res. 2014;41(1):37\u201349. https:\/\/doi.org\/10.1007\/s11414-013-9333-3.","journal-title":"J Behav Health Serv Res"},{"issue":"1","key":"5103_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jsat.2005.03.004","volume":"29","author":"J Carey","year":"2005","unstructured":"Carey J, Perlman DC, Friedmann P, et al. Knowledge of hepatitis among active drug injectors at a syringe exchange program. J Subst Abus Treat. 2005;29(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jsat.2005.03.004.","journal-title":"J Subst Abus Treat"},{"key":"5103_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.drugpo.2017.02.006","volume":"47","author":"A Mah","year":"2017","unstructured":"Mah A, Hull MW, DeBeck K, et al. Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals. Int J Drug Policy. 2017;47:137\u201343. https:\/\/doi.org\/10.1016\/j.drugpo.2017.02.006.","journal-title":"Int J Drug Policy"},{"key":"5103_CR32","doi-asserted-by":"publisher","unstructured":"Wohl DA, Allmon AG, Evon D, et al. Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies. Open Forum Infect Dis. 2017;4(2):ofx095. doi:https:\/\/doi.org\/10.1093\/ofid\/ofx095.","DOI":"10.1093\/ofid\/ofx095"},{"issue":"5","key":"5103_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2105\/AJPH.2012.301069","volume":"103","author":"ML Hatzenbuehler","year":"2013","unstructured":"Hatzenbuehler ML, Phelan JC, Link BG. Stigma as a fundamental cause of population health inequalities. Am J Public Health. 2013;103(5):813\u201321. https:\/\/doi.org\/10.2105\/AJPH.2012.301069.","journal-title":"Am J Public Health"},{"issue":"Suppl 2","key":"5103_CR34","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1093\/cid\/cit263","volume":"57","author":"C Treloar","year":"2013","unstructured":"Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis. 2013;57(Suppl 2):S51\u20135. https:\/\/doi.org\/10.1093\/cid\/cit263.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05103-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T23:13:50Z","timestamp":1622243630000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05103-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5103"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05103-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"4 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by the institutional review board of the University of California, San Francisco. Written informed consent was obtained from each participant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mandana Khalili is a recipient of research grant (to her institution) from Gilead Sciences Inc., and Intercept Pharmaceuticals and she has served as consultant for Gilead Sciences Inc. Jesse Powell is a recipient of research grant from Gilead Sciences Inc. and Abbvie Inc. and he has served on advisory board for Gilead Sciences Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"386"}}